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Abstract: Cutaneous leishmaniasis (CL) is a major tropical infection of public health importance. It is caused by a 
group of protozoan intracellular parasites. Several factors contribute to the prevalence and transmission of CL. More 
than 1400 cases of CL were reported in Saudi Arabia in 2012. Although several studies have looked at CL in Saudi 
Arabia and emphasized on the Eastern province of the country, the highest prevalence of CL was reported in Al-
Qaseem area. In this review, we report on the species of Leishmania parasites causing CL in Saudi Arabia, its 
distribution and its incidence in the past seven years. We also report on the methods used to diagnose this infection 
and the treatment protocols used to treat CL in the country. 
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1. Introduction 
 
Cutaneous leishmaniasis is a major tropical 
infection of public health importance. It is caused by a 
group of protozoan intracellular parasites belonging to 
the order of kinetoplastida. The disease is found in over 
70 countries and 90% of cases occur in Afghanistan, 
Algeria, Brazil, Pakistan, Peru, Saudi Arabia, and Syria. 
The disease is endemic in 18 out of 23 Middle Eastern 
countries [1, 2]. There are over one million cases of 
cutaneous leishmaniasis reported worldwide in the past 
five years [3]. In Saudi Arabia, there are over 19,000 
cases of CL were reported in the past 7 years. Different 
species of the Leishmania parasite have been isolated 
and incriminated as the causative species [2, 4-9]. In 
this review we report on the current status of CL in 
Saudi Arabia, the diagnostic methods used in different 
health sectors, treatment, and control of the disease. 
 
2. The parasite 
 
There are more than 20 Leishmania species that are 
transmitted to humans by the bites of infected female 
phlebotomine sandflies [3]. A few species can cause 
visceral leishmaniasis, others cause cutaneous 
leishmaniasis and some may disseminate into 
mucocutaneous leishmaniasis (Table 1) [1]. Clinically, 
cutaneous leishmaniasis lesions usually appear as 
localized lesions. However, some species can cause 
diffused cutaneous lesions. Morphologically, there are 
two developmental stages of the parasite. Amastigotes 
are small spherical non-flagellated cells measuring from 
2-4µm in diameter with a nucleus and kinetoplast that 
are surrounded by vacuolated cytoplasm. These forms 
are seen in mammalian hosts and are intracellular forms 
(Fig. 1). Promastigotes, or vector form, are thin, 
elongate cells with an anterior kinetoplast and an 
emergent free flagellum measuring from 5-14µm in 
length (Fig. 2). It is not possible to differentiate 
between species of Leishmania morphologically. 
However, Leishmania parasites can be differentiated 
according to the geographical, biological, molecular 
and clinical features of the disease. 
Humans acquire CL infection through a bite of an 
infected female phlebotomine sand fly. Promastigotes 
enter the human circulation and are engulfed by 
macrophages and transform into amastigotes. The 
change in host temperature and surrounding pH triggers 
such transformation [10, 11].  
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Table 1. Leishmania species that cause cutaneous leishmaniasis [1, 12]. 
 
Leishmania species Vertebrate host other than humans Disease Geographical distribution 
L. aethiopica Hyraxes LCL, DCL Ethiopia, Kenya 
L. tropica Dogs, rodents LCL Central Asia, middle east, parts of North Africa, Southeast Asia 
L. tropica major Dogs, rodents LCL Central Asia, North Africa, middle east, East Africa 
L. peruviana Dogs LCL Peru 
L. mexicana mexicana Rodents LCL, DCL Central America, Mexico, USA 
L. mexicana amazonensis Rodents LCL, DCL South America 
L. mexicana pifanoi Rodents LCL Venezuela 
L. braziliensis Rodents, sloths LCL, MCL Mexico, Brazil 
L. panamensis Rodents LCL, MCL Northern South America, Southern Central America 
L. guyanensis Rodents LCL South America 
L. venezuelensis Rodents LCL Northern South America 
LCL = localized cutaneous leishmaniasis;  
DCL = diffused cutaneous leishmaniasis;  
MCL = Muco-cutaneous leishmaniasis. 
 
 
 
Fig. 1. Amastigotes of Leishmania (A = Light micrograph; B = Scanning Electron micrograph). 
 
 
 
Fig. 2. Promastigotes of Leishmania (A = Light micrograph; B = Scanning Electron micrograph). 
 
3. Current status of CL in KSA 
 
In Saudi Arabia, CL is more common in males 
(77.5%) and appears to be more prevalent in adults 
(66.2%) [2, 4-9]. This could be due to the customs used 
by females in Saudi Arabia, which requires the 
reporting of most of the body and because males in 
Saudi Arabia tend to be more exposed to the sand fly 
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than females for most of the working force in Saudi 
Arabia are males. Overall, it is found in equal 
percentages between Saudis and non-Saudis. Saudi 
Arabia has 13 provinces. CL is more prevalent in Al-
Qaseem area and least prevalent in Al-Jouf area. 
However, CL is known to be under reported. CL has 
been known in Saudi Arabia for a very long time. It was 
considered to be of minor importance until 1975. Later, 
it was considered one of the challenging diseases that 
were put on the control scope of the Ministry of Health 
[9]. At that time, no surveys were done to estimate the 
prevalence of CL in Saudi Arabia and data were 
collected from patients attending clinics [13]. Several 
factors have contributed to the increase in transmission 
of CL in Saudi Arabia, including rapid urbanization, 
migration, intensive agriculture, poor living conditions 
at farms, and massive immigration. After the setup of a 
national control program, number of cases of CL have 
dropped. However, several areas in Saudi Arabia are 
still considered endemic for CL [2, 4-9]. 
CL caused by L. major has been reported in many 
parts of Saudi Arabia, including Al-Hasa, Al-Madinah 
Al-Munawarah, Al-Qaseem, Riyadh and the Eastern 
Province while CL caused by L. tropica is endemic in 
the southwestern part of the country only [13-15]. 
Moreover, L. tropica have been isolated from CL in 
canines in the Eastern Province [16]. Furthermore, L. 
tropica was implicated as the causative agent of 
visceral leishmaniasis in Gulf War veterans [17]. 
However, a 46 year retrospective study of leishmaniasis 
cases in the Eastern Province found no evidence of 
dissemination or viscerotopic syndrome in patients seen 
at the Saudi Aramco hospital in the Eastern Province 
[18] and the potential for dissemination due to 
cutaneous leishmaniasis was significantly higher in 
individuals from non-endemic areas than those living in 
endemic areas [19]. In the past seven years over 19,000 
of CL have been reported in Saudi Arabia with the 
highest prevalence in Al-Qaseem province (Table 2 and 
Fig. 3) [2, 4-9]. However, Amin and colleagues 
reported a declining trend in the incidence of CL in Al-
Hasa area [20]. Phlebotomus papatasi was incriminated 
as the transmitting vector in Al-Hasa area [13, 21] 
while P. sergenti was identified as the transmitting 
vector of L. tropica in the southwestern part of the 
country [22].  
 
Table 2. Cases of CL reported in Saudi Arabia in from 2006 – 2012. 
 
Area Year Total 
2006 2007 2008 2009 2010 2011 2012 
Riyadh 306 305 325 235 401 230 135 1937 
Makkah Al-Mukarramah 64 51 57 35 21 14 18 260 
Al-Madinah Al-Munawarah 643 619 287 626 1000 405 236 3816 
Al-Qaseem 981 851 758 654 1464 534 368 5610 
Eastern Province 900 833 397 460 470 227 289 3576 
Aseer 145 148 137 181 271 204 139 1225 
Tabouk 149 165 90 106 159 125 97 891 
Hail 249 189 165 186 234 117 122 1262 
Northern Borders 3 0 0 0 1 0 0 4 
Jazan 46 51 63 28 81 75 31 375 
Najran 70 30 12 15 15 11 18 171 
Al-Baha 45 44 30 23 12 9 11 174 
Al-Jouf 1 0 0 0 0 0 0 1 
Total 3602 3286 2321 2549 4129 1951 1464 19302 
 
 
 
 
Fig. 3. Incidence of CL in different provinces of Saudi Arabia. 
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4. Diagnostic methods used to diagnose CL 
 
In addition to clinical diagnosis, microscopic 
examination of skin biopsy or scraping can be used for 
the diagnosis of CL by identifying the amastigotes of 
Leishmania in the specimen. Biopsy and aspirate 
materials can be also cultured in NNN medium or 
Schneider’s liquid medium to detect the promastigote 
stage of the parasite. Furthermore, such material can be 
injected into a suitable laboratory mouse or hamster and 
recover the parasites later on. However, Goto and his 
colleagues reported a low sensitivity of the direct 
examination techniques, culture techniques and animal 
inoculation techniques at approximately 50-70%, 44-
58%, and 38-52% respectively [23-25]. 
Immunohistochemistry is a better technique in 
terms of sensitivity to detect Leishmania amastigotes 
and antigen reaching 41.4% and 88.5%, respectively 
[26]. These methods require skilled laboratory 
personnel and take a long time to accomplish. In 
addition, they are unable to identify the Leishmania 
species diagnosed. Therefore, the researcher's effort 
was aimed at developing molecular tools to assess in 
the detection of Leishmania DNA and hence diagnose 
the infection.  
Leishmanin, or Montenegro test, is delayed-type 
hypersensitivity skin test that is used to diagnose 
leishmaniasis. However, this test cannot differentiate 
between active and past infections. Nowadays, this test 
is rarely used and its use is mainly confined to 
epidemiological studies. This is because it can give 
positive results in CL cases even after treatment and 
false positive results in cases that never showed any 
symptoms and live in endemic areas [23, 27-29]. 
Immunofluorescence and ELISA are more 
commonly used serological test to diagnose 
leishmaniasis. However, such laborious techniques can 
show a high degree of cross reactivity and are of low 
sensitivity reaching up to 88% [23, 30-33]. The direct 
agglutination test (DAT) is another serological test that 
can be used to diagnose leishmaniasis. The test is 
highly specific and sensitive when using homogenous 
species antigens but its specificity and sensitivity are 
questionable if using heterogeneous species antigen 
[23, 34]. 
Molecular techniques for the diagnosis of 
Leishmania parasites have emerged and evolved since 
the 80's [35-39]. Recently, Yehia and colleagues 
described a rapid and optimized protocol from DNA 
extraction to leishmaniasis sub-speciation, which sowed 
showed high sensitivity and specificity in confirming 
clinically suspected cases [40]. Molecular techniques 
have been used for the confirmation of clinically 
diagnosed CL cases in Saudi Arabia. El-Beshbishy and 
his group described the use of internal transcribed 
spacer 1 (ITS1) PCR-restriction fragment length 
polymorphism (RFLP) and kinetoplast DNA (kDNA) 
PCR to diagnose CL cases caused by L. major and L. 
tropica in Al-Madinah Al-Munawarah. In their study, 
they reported that kDNA PCR had a sensitivity of 
90.7%, whereas ITS1 PCR had a sensitivity of 70.1%, 
while parasite culture alone detected 39.2% and smear 
alone 55.3% of the positive samples. With the 
exception of kDNA PCR, all other assays were 100% 
specific [41]. 
 
5. Treatment 
 
CL is considered a self-healing disease. Lesions 
usually heal within 1-5 years. However, it is quite 
justified to use drugs to treat CL to minimize the 
resultant scar tissue caused by the lesion. Sodium 
stibogluconate, a pentavalent antimony compound, 
have been used to treat CL for 70 years. Today, 
pentavalent antimonials are the most widely used drugs 
to treat leishmaniasis. Pentamidine have been used to 
treat leishmaniasis as it acts on the kDNA of the 
parasite. However, this drug acts more slowly than 
pentavalent antimonials [42]. 
Antifungal compounds have been used also to treat 
CL. Ketoconazole, clotrimazole, miconazole, 
fluconazole and itraconazole, have been reported to 
have antileishmanial activity [42-46]. The use of oral 
rifampicin in the treatment of CL is reported to be a 
valuable, safe, easy to administer and cheaper modality 
for the treatment of CL. The advantage of rifampicin 
over other drugs is that it is more accepted than 
injectable drugs, especially by children [47]. 
Terbinafine was also tested in vitro and in vivo to 
evaluate its effect on L. major promastigotes and 
lesions in mice. Its efficacy in causing growth arrest in 
cultures and reducing the lesion size in mice is still 
questionable [43, 48]. Amphotericin B is one of the 
polyene antibiotics effective against various fungi and 
Leishmania. It was reported that this drug has 
leishmanicidal activity, but it is still rarely used due to 
its toxic effect [42]. Unfortunately, there is no 
consistent method used in treating CL. Moreover, there 
are no differences between treatment of single and 
multiple lesions [49]. This would emphasize the 
necessity to set clear guidelines for treatment of CL in 
Saudi Arabia and worldwide. 
 
6. Conclusion 
 
In conclusion, cutaneous leishmaniasis is still 
considered an endemic disease in Saudi Arabia even 
though its incidence is declining. More studies are 
required to reassess its epidemiology in the country and 
more effort should be made to control the disease and 
reduce its prevalence. Furthermore, strict guidelines for 
the treatment of CL and the drug dose to be used in 
Saudi Arabia should be implemented and enforced. 
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